Tweets
Using data from a large population > 100 million people with SpA (predominantly PsA) from the TriNetX Global Collaborative Network, JAKi was not associated with increased risk of CVD, VTE or selected cancers, compared to TNFi or IL-17i #EULAR2024 Abstract P0231 @RheumNow https://t.co/Oi64BeWcmk
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 8 months ago
Patients with r-axSpA can be divided into subgroups with specific pain distribution profiles and sensory symptom profiles (Clusters 1,2,3) 1 with a diffuse distribution of pain over many pain regions indicates activation of the nociplastic pain mechanisms, 2 with pain localised… https://t.co/HsaBzlXzoc https://t.co/CpMPzNWptk
Links:
Dr. Antoni Chan @synovialjoints ( View Tweet )
1 year 8 months ago
Molecular dissection of OA mechanisms brings some important pieces of knowledge and new potential therapeutic targets
GWAS in hands OA
#EULAR2024 @RheumNow https://t.co/L7iZgzmFtr
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
Get your sunscreen ready 🌞!
Higher UV-B exposure asso w/ higher chance of reaching ACR/EULAR Boolean remission in RA pts treated w/ MTX monotherapy
Now this could well be a surrogate for other socio demographic factors asso with better prognosis
@RheumNow #EULAR2024 OP0153 https://t.co/k852O5psTM
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
Nationwide turkish cohort study e.PULSE
347000+ pts
Gender based comorbidity analysis
Female asso w/ higher
-accompanying CTD OR 3.75
-asthma OR 2.06
-depression OR 2.38
-fibromyalgia OR 3.16
and lesser
- COPD OR 0.34
- ILD OR 0.60
-Malignancy OR 0.63
@RheumNow #EULAR2024 OP0175
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
When to administrate the PCV13 in RA?
VACIMRA study 276pts randomized
PCV13 + MTX = 75% humoral response
PCV13 + MTX 1 month later = 88% humoral response
No diff on dis control & GCs or DMARDs use
#EULAR2024 @RheumNow AbstOP0140
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
#EULARBest @RheumNow https://t.co/cCv88iTCTV
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
ARGO trial Ph 2 RCT Sonelokimab IL-17A/Fi Nanobody
Wk 12, primary ACR50
ACR 50 SON 120 mg 46% 60 mg 46% PBO 20%
PASI 90 SON 120 mg 60% 60 mg 77% PBO 15%
MDA SON 60mg 47% PBO 20%
No new safety signal
#EULAR2024 @RheumNow AbstrOP0195 https://t.co/4W5KFi23za
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PH 2/3 STUDY OF SHR0302, A SELECTIVE JAK 1 INHIBITOR, IN PATIENTS WITH ACTIVE AS - behaves like a JAK in AxSpA now as well as in RA - safety is clean/no new signals but where is the zoster? @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 8 months ago
Baseline predictors of D2TRA in naive recent onset RA 1000pts
-female sex
-higher joint count
-erosions
-pulmonary involvement
-depression
-fatigue
#EULAR24 AbstOP0118 @RheumNow
Aurelie Najm @AurelieRheumo ( View Tweet )
1 year 8 months ago
COMPARATIVE SAFETY OF JAK INHIBITORS VERSUS TNF OR IL-17 INHIBITORS FOR CARDIOVASCULAR DISEASE, VENOUS THROMBOEMBOLISM AND CANCER IN PSORIATIC ARTHRITIS AND AXIAL - no signal of significant difference but channeling bias last few years @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 8 months ago
COMPARATIVE RISK OF MORTALITY IN NEW USERS OF PRESCRIPTION OPIOIDS FOR NON-CANCER PAIN: RESULTS FROM THE INTERNATIONAL PHARMACOSURVEILLANCE STUDY - HR 9-13 increased deaths narcotic use compared with codeine UK Boston Montreal >1 million pts included @RheumNow #EULAR2024
Peter Nash @drpnash ( View Tweet )
1 year 8 months ago
